AstraZeneca and Sanofi Announce Big Breakthrough With RSV Vaccine

Respiratory syncytial virus (RSV) infections cause about 80,000 hospitalizations in children and 500 deaths each year. AstraZeneca and Sanofi announced that their MELODY Phase III trial of nirsevimab hit the primary endpoint in medically attended lower respiratory tract infections (LRTI) caused by RSV in healthy late preterm and term infants. This moves the drug one step closer to becoming the first new RSV treatment in 23 years.